T The Guardian · 4 h ago Follow Health

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group. Continue…

Read on theguardian.com

This story comes from The Guardian's feed; the full article and all rights belong to the source.

0 0

#Ozempic #Mounjaro #insulin #GLP-1

Comments (0)

No comments yet. Be the first to comment.

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

Comments (0)

Related news

People in deprived areas of England more than twice as likely to die early, study shows

The vaccine limbo in the US is worsening the measles outbreak

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

Seven days of chaos in the ER: How this country's healthcare system is unraveling

Scots urged to use A&E 'only when necessary' amid 'significant pressures'

How word of mouth is helping an Amish community's fight against measles

Police investigate as nearly 30 Santa Barbara half-marathon runners fall ill with ‘unusual symptoms’

Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

These states are offering extra ACA premium subsidies in 2027

More women are using rage rooms, but are they therapy or just a quick release? | BBC News

Popular Nintendo Blogger Supper Mario Broth Says He May Only Have a Year to Live

Nebraska rushed Medicaid work rules. Then a cancer patient was told he'd lost coverage

Two mums take on a drugs company to fight for their children

GPs to offer 300,000 patients extra support to ease winter strain on NHS

Half of NHS trusts in England lack funds earmarked to cover maternity leave

Stimulant overdoses on the rise as opioid deaths decline, but treatment is complex

In Maine, a new approach to practicing medicine in the sky

Psychiatrists and paediatricians among specialists most likely to charge ‘extreme’ fees, thinktank finds

There's finally a treatment for my five-year-old's dementia - but it'll cost me £3m

My parents chose to die together and I was left to grieve alone

Rise in NHS birth centre closures ‘shocking’ denial of women’s rights, experts say

The UV-tracking Gem made me rethink how sunlight affects my health, not just my appearance

A promising new medicine against heart disease fails unexpectedly

New trial for Ebola vaccine